Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
NCT02172755
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Epilepsy
Interventions
DRUG:
BIA 2-093
Sponsor
Bial - Portela C S.A.